1. Home
  2. NVNO
  3. NVNO News

Latest enVVeno Medical Corporation (NVNO) News on June 23, 2025

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
NVNO

ACCESS Newswire

17 days ago

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer
NVNO

ACCESS Newswire

a month ago

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery
NVNO

ACCESS Newswire

a month ago

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24
NVNO

ACCESS Newswire

2 months ago

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium
NVNO

ACCESS Newswire

2 months ago

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment
NVNO

ACCESS Newswire

2 months ago

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium
NVNO

ACCESS Newswire

3 months ago

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

NVNO

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 03/14/2025

NVNO

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 03/13/2025

NVNO

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 03/12/2025

NVNO

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 03/11/2025

NVNO

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 03/10/2025

NVNO

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 03/07/2025

NVNO

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 03/06/2025

NVNO

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 03/05/2025

NVNO

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 03/04/2025

NVNO

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 03/03/2025

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25
NVNO

ACCESS Newswire

4 months ago

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

NVNO

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 02/28/2025

NVNO

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 02/27/2025

NVNO

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 02/26/2025

NVNO

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 02/25/2025

NVNO

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 02/24/2025

NVNO

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 02/21/2025

NVNO

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 02/20/2025

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
NVNO

ACCESS Newswire

4 months ago

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum
NVNO

ACCESS Newswire

4 months ago

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

NVNO

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 02/19/2025

NVNO

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 02/18/2025

NVNO

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 02/14/2025

NVNO

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 02/13/2025

NVNO

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 02/12/2025

NVNO

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 02/11/2025

NVNO

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 02/10/2025

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting
NVNO

ACCESS Newswire

5 months ago

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

NVNO

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 01/31/2025

NVNO

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 01/30/2025

NVNO

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 01/29/2025

NVNO

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 01/28/2025

NVNO

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 01/27/2025

NVNO

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 01/24/2025

NVNO

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 01/23/2025

NVNO

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 01/22/2025

NVNO

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 01/21/2025

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth
NVNO

Simply Wall St.

5 months ago

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

NVNO

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 01/17/2025

NVNO

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 01/16/2025

NVNO

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 01/15/2025

NVNO

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 01/14/2025

NVNO

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 01/13/2025

NVNO

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 01/09/2025

NVNO

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 01/08/2025

NVNO

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 01/07/2025

NVNO

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 01/06/2025

NVNO

Argus Research

6 months ago

Daily – Vickers Top Buyers & Sellers for 01/06/2025

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe
NVNO

ACCESSWIRE

6 months ago

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website
NVNO

ACCESSWIRE

7 months ago

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium
NVNO

ACCESSWIRE

7 months ago

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval
NVNO

ACCESSWIRE

7 months ago

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year
NVNO

ACCESSWIRE

8 months ago

enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year

enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)
NVNO

ACCESSWIRE

8 months ago

enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)

enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering
NVNO

ACCESSWIRE

9 months ago

enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

enVVeno Medical Corporation Announces Proposed Public Offering
NVNO

ACCESSWIRE

9 months ago

enVVeno Medical Corporation Announces Proposed Public Offering

enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing
NVNO

ACCESSWIRE

10 months ago

enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing

enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)
NVNO

ACCESSWIRE

10 months ago

enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)

Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation
NVNO

Simply Wall St.

10 months ago

Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation

enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update
NVNO

ACCESSWIRE

a year ago

enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
NVNO

ACCESSWIRE

a year ago

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting
NVNO

ACCESSWIRE

a year ago

Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting

New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024
NVNO

ACCESSWIRE

a year ago

New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024

enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
NVNO

ACCESSWIRE

a year ago

enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update

Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
NVNO

ACCESSWIRE

a year ago

Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium

New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
NVNO

ACCESSWIRE

a year ago

New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
NVNO

ACCESSWIRE

a year ago

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer

enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
NVNO

ACCESSWIRE

a year ago

enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
NVNO

ACCESSWIRE

a year ago

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth
NVNO

Simply Wall St.

a year ago

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
NVNO

ACCESSWIRE

a year ago

enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
NVNO

ACCESSWIRE

a year ago

Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024

Brady Corporation (BRC) Hit a 52 Week High, Can the Run Continue?
NVNO

Zacks

a year ago

Brady Corporation (BRC) Hit a 52 Week High, Can the Run Continue?

Academic Report by Pixie Dust Technologies, Inc. Showcases Applicability of Gamma Wave Sound
NVNO

PR Newswire

a year ago

Academic Report by Pixie Dust Technologies, Inc. Showcases Applicability of Gamma Wave Sound

Lakeland Industries Declares Cash Dividend for First Quarter 2025
NVNO

ACCESSWIRE

a year ago

Lakeland Industries Declares Cash Dividend for First Quarter 2025

With 40% ownership, Pixie Dust Technologies, Inc. (NASDAQ:PXDT) insiders have a lot riding on the company's future
NVNO

Simply Wall St.

a year ago

With 40% ownership, Pixie Dust Technologies, Inc. (NASDAQ:PXDT) insiders have a lot riding on the company's future

Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?
NVNO

Zacks

a year ago

Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?

NVNO

Associated Press Finance

a year ago

CB Financial Services: Q4 Earnings Snapshot

NVNO

Business Wire

a year ago

CB Financial Services, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results and Declares Quarterly Cash Dividend

Investing in Provident Financial Holdings (NASDAQ:PROV) five years ago would have delivered you a 1.9% gain
NVNO

Simply Wall St.

a year ago

Investing in Provident Financial Holdings (NASDAQ:PROV) five years ago would have delivered you a 1.9% gain

Invesco Closed-End Funds Declare Dividends
NVNO

PR Newswire

a year ago

Invesco Closed-End Funds Declare Dividends

NVNO

GuruFocus.com

a year ago

Provident Financial Holdings Inc Reports Mixed Fiscal Q2 Results Amid Economic Uncertainty

Provident Financial (PROV) Surpasses Q2 Earnings Estimates
NVNO

Zacks

a year ago

Provident Financial (PROV) Surpasses Q2 Earnings Estimates

Will Connect Biopharma Holdings (NASDAQ:CNTB) Spend Its Cash Wisely?
NVNO

Simply Wall St.

a year ago

Will Connect Biopharma Holdings (NASDAQ:CNTB) Spend Its Cash Wisely?

Chemung Financial (CHMG) Reports Q4 Earnings: What Key Metrics Have to Say
NVNO

Zacks

a year ago

Chemung Financial (CHMG) Reports Q4 Earnings: What Key Metrics Have to Say

Iteris Sets Fiscal Third Quarter 2024 Conference Call for Thursday, February 8, 2024 at 4:30 p.m. ET
NVNO

Business Wire

a year ago

Iteris Sets Fiscal Third Quarter 2024 Conference Call for Thursday, February 8, 2024 at 4:30 p.m. ET

Insiders own 28% of Annovis Bio, Inc. (NYSE:ANVS) shares but individual investors control 57% of the company
NVNO

Simply Wall St.

a year ago

Insiders own 28% of Annovis Bio, Inc. (NYSE:ANVS) shares but individual investors control 57% of the company

Eton Pharmaceuticals (NASDAQ:ETON) investors are sitting on a loss of 50% if they invested three years ago
NVNO

Simply Wall St.

a year ago

Eton Pharmaceuticals (NASDAQ:ETON) investors are sitting on a loss of 50% if they invested three years ago

ClearPoint Neuro Announces First EU MDR Certification Success and Approval to Ship Product to Europe
NVNO

GlobeNewswire

a year ago

ClearPoint Neuro Announces First EU MDR Certification Success and Approval to Ship Product to Europe

American Resources' (AREC) Arm Executes MOU With Duesenfeld
NVNO

Zacks

a year ago

American Resources' (AREC) Arm Executes MOU With Duesenfeld

Jisoo Is New Face of Alo Yoga; Pucci Debuts Yoga Collection
NVNO

WWD

a year ago

Jisoo Is New Face of Alo Yoga; Pucci Debuts Yoga Collection

NVNO

Footwear News

a year ago

Allbirds Names New Chief Marketing Officer and Chief Design Officer Amid Ongoing Transformation Plan

Allbirds Announces Executive Leadership Appointments
NVNO

GlobeNewswire

a year ago

Allbirds Announces Executive Leadership Appointments

Share on Social Networks: